The main value of subtyping ischemic stroke patients is for a better therapeutic decision-making process and to minimize time-to-thrombosis with the treatment of intervenors tissue plasminogen activator (IV-tPA) [4]. This evidence concerns the gene PLAT and ischemic stroke.